Search

Your search keyword '"Fine, Nowell"' showing total 213 results
Start Over Author "Fine, Nowell" Search Limiters Peer Reviewed
213 results on '"Fine, Nowell"'

3. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis: Insights From THAOS

Author

Emdin, Michele, Hanna, Mazen, Azevedo, Olga, Lino Cirami, Calogero, Gonzalez Costello, Jose, Slosky, David, Moelgaard, Henning, Nativi Nicolau, Jose, Hummel, Scott, Jeon, Eun-Seok, Fine, Nowell, Murali, Srinivas, Miller, Edward, Shah, Sanjiv, Witteles, Ronald, Waddington-Cruz, Marcia, Lenihan, Daniel, Sekijima, Yoshiki, Van Cleemput, Johan, Correia, Edileide de Barros, Cariou, Eve, Quan, Dianna, Freimer, Miriam, Steidley, David, Hüsing-Kabar, Anna, Plante-Bordeneuve, Violaine, Nienhuis, Hans, Wixner, Jonas, Ralph, Jeffrey, Ventura, Hector, Zivkovic, Sasa, Delgado, Diego, Fernandéz Torrón, Roberto, Gottlieb, Stephen, Cotts, William, Tallaj, Jose, Brunkhorst, Robert, Polydefkis, Michael, Mueller, Christopher, Tschoepe, Carsten, Gonzalez Moreno, Juan, Sarswat, Nitasha, Luo, Jin, Tauras, James, Warner, Alberta, Mora-Ayestaran, Nerea, Dispenzieri, Angela, Kristen, Arnt V., Maurer, Mathew S., Diemberger, Igor, Drachman, Brian M., Grogan, Martha, Gupta, Pritam, Glass, Oliver, Amass, Leslie, and Garcia-Pavia, Pablo

Published
2024
Full Text
View/download PDF

5. The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology

Author

STERN, LILY K., GRODIN, JUSTIN L., MAURER, MATHEW S., RUBERG, FREDERICK L., PATEL, AYAN R., KHOURI, MICHEL G., ROTH, LORI R., ARAS, MANDAR A., BHARDWAJ, ANJU, BHATTACHARYA, PRIYANKA, BRAILOVSKY, YEVGENIY, DRACHMAN, BRIAN M., EBONG, IMO A., FINE, NOWELL M., GAGGIN, HANNA, GOPAL, DEEPA, GRIFFIN, JAN, JUDGE, DANIEL, KIM, PAUL, MITCHELL, JOSHUA, MITTER, SUMEET S., MOHAN, RAJEEV C., RAMOS, HANNIA, REYENTOVICH, ALEX, SHEIKH, FAROOQ H., SPERRY, BRETT, CARTER, SPENCER, UREY, MARCUS, VAISHNAV, JOBAN, VEST, AMANDA R., KITTLESON, MICHELLE M., and PATEL, JIGNESH K.

Published
2024
Full Text
View/download PDF

19. Mid-wall striae fibrosis predicts heart failure admission, composite heart failure events, and life-threatening arrhythmias in dilated cardiomyopathy

Author

Purmah, Yanish, Cornhill, Aidan, Lei, Lucy Y., Dykstra, Steven, Mikami, Yoko, Satriano, Alessandro, Labib, Dina, Flewitt, Jacqueline, Rivest, Sandra, Sandonato, Rosa, Seib, Michelle, Howarth, Andrew G., Lydell, Carmen P., Heydari, Bobak, Merchant, Naeem, Bristow, Michael, Kolman, Louis, Fine, Nowell M., and White, James A.

Published
2022
Full Text
View/download PDF

22. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey

Author

Barroso, Fabio Adrian, Van Cleemput, Johan, Fine, Nowell, Schmidt, Hartmut, Gess, Burkhard, Moelgaard, Henning, Planté-Bordeneuve, Violaine, Adams, David, Inamo, Jocelyn, Vita, Giuseppe, Cirami, Calogero Lino, Luigetti, Marco, Emdin, Michele, Sekijima, Yoshiki, Yamashita, Taro, Jeon, Eun-Seok, Gonzalez Duarte Briseno, Maria Alejandra, Nienhuis, Hans, Azevedo, Olga, Campistol Plana, Josep Maria, Moreno, Juan Gonzalez, Costello, Jose Gonzalez, Wixner, Jonas, Parman, Yesim, Shah, Sanjiv, Quan, Dianna, Marburger, Tessa, Polydefkis, Michael, Gottlieb, Stephen, Ralph, Jeffrey, Sarswat, Nitasha, Luo, Jin, Murali, Srinivas, Cotts, William, Drachman, Brian, Steidley, David, Hummel, Scott, Slosky, David, Ventura, Hector, Jacoby, Daniel, Hoffman, James, Tauras, James, Zivkovic, Sasa, Tallaj, Jose, Lenihan, Daniel, Mueller, Christopher, Nativi-Nicolau, Jose, Siu, Alfonso, Dispenzieri, Angela, Maurer, Mathew S., Rapezzi, Claudio, Kristen, Arnt V., Garcia-Pavia, Pablo, LoRusso, Samantha, Waddington-Cruz, Márcia, Lairez, Olivier, Witteles, Ronald, Chapman, Doug, Amass, Leslie, and Grogan, Martha

Published
2021
Full Text
View/download PDF

26. Baseline Predictors of Adverse Outcomes for Transthyretin Amyloidosis Cardiomyopathy Patients Treated and Untreated with Tafamidis: A Canadian Referral Center Experience.

Author

Shahi, Karan, Miller, Robert J. H., Dykstra, Steven, Feng, Yuanchao, Howlett, Jonathan G., Jimenez-Zepeda, Victor, Veenhuyzen, Jan, White, James A., and Fine, Nowell M.

Subjects
SYSTOLIC blood pressure, KIDNEY physiology, TRANSTHYRETIN, MORTALITY, COMPETING risks, CARDIAC amyloidosis
Abstract

Background: Tafamidis is a costly therapy that improves outcomes for patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), although significant knowledge gaps exist for predicting longer-term response to treatment. The purpose of this study was to examine baseline predictors of adverse outcomes and their association with tafamidis treatment in comparison with those untreated in a clinical cohort from a Canadian ATTR-CM referral center. Methods: Patients with a confirmed diagnosis of ATTR-CM were included. Multivariable modeling was used to identify baseline variables associated with the primary outcome of all-cause mortality and secondary outcomes of cardiovascular mortality or hospitalization. Cox proportional hazard and competing risk analyses were used, with tafamidis modeled as a time-varying covariate. Results: In total, 139 ATTR-CM patients were included, with a median age of 80.9 years [74.3–86.6 years], from 2011 to 2022. The mean follow-up was 2.9 ± 1.8 years. Eighty (55%) patients were treated with tafamidis. All-cause mortality and cardiovascular mortality alone were associated with the following baseline variables: age, clinical frailty scale, systolic blood pressure, renal function, and right ventricular size and function (all p < 0.05), with no identified interactions with tafamidis treatment. Only baseline renal function was associated with cardiovascular hospitalization (p < 0.05). Conclusion: Important baseline variables associated with adverse ATTR-CM disease outcomes included renal function, systolic blood pressure, frailty, and right ventricular size and function. The risk factors were independent of treatment with tafamidis. These findings may help improve risk stratification for determining eligibility for ATTR-CM therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.

Author

Lewis, Ellen, Fine, Nowell, McCulloch, Sylvia, Tay, Jason, Duggan, Peter, Neri, Paola, Bahlis, Nizar, and Jimenez-Zepeda, Victor H.

Subjects
*PROGRESSION-free survival, *AMYLOIDOSIS, *CARDIAC patients, *DOXYCYCLINE, *CARDIAC amyloidosis, *BORTEZOMIB
Abstract

Background: Pre-clinical and retrospective data suggest that doxycycline added to treatment regimens has benefit in AL amyloidosis. However, a recent multicenter, open-label, randomized controlled trial in AL amyloidosis patients treated with CyBorD did not demonstrate a progression-free survival (PFS) or cardiac PFS benefit with added doxycycline. Objective: The main objective of this study was to explore the role of doxycycline combined with bortezomib-containing regimens (BCRs) for newly diagnosed AL amyloidosis patients with cardiac involvement and to compare them with a cohort of concurrent patients treated with BCR only. Material and Methods: AL amyloidosis patients, newly diagnosed between January 2012 and March 2022, who were treated with BCR at the Amyloidosis Program of Calgary (APC) were evaluated. Results: Sixty-four concurrent patients were identified. Thirty-nine patients received doxycycline in addition to BCR (BCR-D) for a median of 8 months. The overall response rate was similar among the groups. No significant differences in VGPR/CR, dFLC at 1 month, time to first response, time to best response, or organ responses were noted between the BCR alone and BCR-D groups. Summary and Conclusions: Our retrospective study demonstrated that doxycycline combined with BCR failed to prolong OS, PFS, or cardiac responses compared with BCR alone in patients with cardiac AL amyloidosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis

Author

Fine, Nowell M., Davis, Margot K., Anderson, Kim, Delgado, Diego H., Giraldeau, Genevieve, Kitchlu, Abhijat, Massie, Rami, Narayan, Jane, Swiggum, Elizabeth, Venner, Christopher P., Ducharme, Anique, Galant, Natalie J., Hahn, Christopher, Howlett, Jonathan G., Mielniczuk, Lisa, Parent, Marie-Claude, Reece, Donna, Royal, Virginie, Toma, Mustafa, Virani, Sean A., and Zieroth, Shelley

Published
2020
Full Text
View/download PDF

32. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis

Author

O’Meara, Eileen, McDonald, Michael, Chan, Michael, Ducharme, Anique, Ezekowitz, Justin A., Giannetti, Nadia, Grzeslo, Adam, Heckman, George A., Howlett, Jonathan G., Koshman, Sheri L., Lepage, Serge, Mielniczuk, Lisa M., Moe, Gordon W., Swiggum, Elizabeth, Toma, Mustafa, Virani, Sean A., Zieroth, Shelley, De, Sabe, Matteau, Sylvain, Parent, Marie-Claude, Asgar, Anita W., Cohen, Gideon, Fine, Nowell, Davis, Margot, Verma, Subodh, Cherney, David, Abrams, Howard, Al-Hesayen, Abdul, Cohen-Solal, Alain, D’Astous, Michel, Delgado, Diego H., Desplantie, Olivier, Estrella-Holder, Estrellita, Green, Lee, Haddad, Haissam, Harkness, Karen, Hernandez, Adrian F., Kouz, Simon, LeBlanc, Marie-Hélène, Lee, Douglas, Masoudi, Frederick A., McKelvie, Robert S., Rajda, Miroslaw, Ross, Heather J., and Sussex, Bruce

Published
2020
Full Text
View/download PDF

33. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable

Author

Brannagan, III, Thomas H., Auer-Grumbach, Michaela, Berk, John L., Briani, Chiara, Bril, Vera, Coelho, Teresa, Damy, Thibaud, Dispenzieri, Angela, Drachman, Brian M., Fine, Nowell, Gaggin, Hanna K., Gertz, Morie, Gillmore, Julian D., Gonzalez, Esther, Hanna, Mazen, Hurwitz, David R., Khella, Sami L., Maurer, Mathew S., Nativi-Nicolau, Jose, Olugemo, Kemi, Quintana, Luis F., Rosen, Andrew M., Schmidt, Hartmut H., Shehata, Jacqueline, Waddington-Cruz, Marcia, Whelan, Carol, and Ruberg, Frederick L.

Published
2021
Full Text
View/download PDF

39. Sex-based differences in the phenotypic expression and prognosis of idiopathic non-ischaemic cardiomyopathy: a cardiovascular magnetic resonance study.

Author

Mallabone, Maggie, Labib, Dina, Abdelhaleem, Ahmed, Dykstra, Steven, Thompson, Richard B, Paterson, D Ian, Thompson, Sam K, Hasanzadeh, Fereshteh, Mikami, Yoko, Rivest, Sandra, Flewitt, Jacqueline, Feng, Yuanchao, Macdonald, Matthew, King, Melanie, Bristow, Michael, Kolman, Louis, Howarth, Andrew G, Lydell, Carmen P, Miller, Robert J H, and Fine, Nowell M

Subjects
LEFT heart ventricle, CARDIOMYOPATHIES, RESEARCH funding, PATIENTS, VENTRICULAR ejection fraction, MYOCARDIAL ischemia, LEFT heart atrium, SEX distribution, HOSPITAL admission & discharge, DESCRIPTIVE statistics, CAUSES of death, HEART failure, FIBROSIS, CARDIOVASCULAR disease diagnosis, MAGNETIC resonance angiography, VENTRICULAR arrhythmia, RIGHT heart atrium, CORONARY angiography, RIGHT heart ventricle, CONFIDENCE intervals, STROKE volume (Cardiac output), PHENOTYPES
Abstract

Aims We sought to characterize sex-related differences in cardiovascular magnetic resonance-based cardiovascular phenotypes and prognosis in patients with idiopathic non-ischaemic cardiomyopathy (NICM). Methods and results Patients with NICM enrolled in the Cardiovascular Imaging Registry of Calgary (CIROC) between 2015 and 2021 were identified. Z -score values for chamber volumes and function were calculated as standard deviation from mean values of 157 sex-matched healthy volunteers, ensuring reported differences were independent of known sex-dependencies. Patients were followed for the composite outcome of all-cause mortality, heart failure admission, or ventricular arrhythmia. A total of 747 patients were studied, 531 (71%) males. By Z -score values, females showed significantly higher left ventricular (LV) ejection fraction (EF; median difference 1 SD) and right ventricular (RV) EF (difference 0.6 SD) with greater LV mass (difference 2.1 SD; P < 0.01 for all) vs. males despite similar chamber volumes. Females had a significantly lower prevalence of mid-wall striae (MWS) fibrosis (22% vs. 34%; P < 0.001). Over a median follow-up of 4.7 years, 173 patients (23%) developed the composite outcome, with equal distribution in males and females. LV EF and MWS were significant independent predictors of the outcome (respective HR [95% CI] 0.97 [0.95–0.99] and 1.6 [1.2–2.3]; P = 0.003 and 0.005). There was no association of sex with the outcome. Conclusion In a large contemporary cohort, NICM was uniquely expressed in females vs. males. Despite similar chamber dilation, females demonstrated greater concentric remodelling, lower reductions in bi-ventricular function, and a lower burden of replacement fibrosis. Overall, their prognosis remained similar to male patients with NICM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

Author

Virani, Sean A., Dent, Susan, Brezden-Masley, Christine, Clarke, Brian, Davis, Margot K., Jassal, Davinder S., Johnson, Christopher, Lemieux, Julie, Paterson, Ian, Sebag, Igal A., Simmons, Christine, Sulpher, Jeffrey, Thain, Kishore, Thavendiranathan, Paaldinesh, Wentzell, Jason R., Wurtele, Nola, Côté, Marc André, Fine, Nowell M., Haddad, Haissam, Hayley, Bradley D., Hopkins, Sean, Joy, Anil A., Rayson, Daniel, Stadnick, Ellamae, and Straatman, Lynn

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results